Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Sells 1,343 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo sold 1,343 shares of the firm’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $11.38, for a total value of $15,283.34. Following the sale, the senior vice president now directly owns 122,330 shares of the company’s stock, valued at $1,392,115.40. This represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Dyne Therapeutics Trading Up 1.4 %

DYN stock opened at $12.05 on Friday. The business’s 50-day moving average price is $14.58 and its two-hundred day moving average price is $25.27. The firm has a market cap of $1.36 billion, a PE ratio of -3.38 and a beta of 1.11. Dyne Therapeutics, Inc. has a 1-year low of $11.18 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. On average, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on DYN. Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Scotiabank began coverage on Dyne Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price for the company. Robert W. Baird began coverage on Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price for the company. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Finally, Piper Sandler lowered their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $48.85.

Institutional Trading of Dyne Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DYN. Quantbot Technologies LP bought a new stake in Dyne Therapeutics during the third quarter worth about $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics during the third quarter worth approximately $36,000. US Bancorp DE increased its position in Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after buying an additional 1,212 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Dyne Therapeutics during the fourth quarter worth approximately $50,000. Finally, KBC Group NV increased its position in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after buying an additional 978 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.